For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Prucalopride - Constipation
PAD Profile : Prucalopride - Constipation
Traffic Light Status
Status 1 of 1.
- Tablets
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Methylnaltrexone bromide
- Naloxegol
- Ispaghula husk
- Bisacodyl
- Docusate sodium
- Glycerol
- Senna
- Lactulose
- Phosphates (Rectal)
- Sterculia
- Co-danthrusate (Dantron/docusate sodium)
- Co-danthramer (Dantron/poloxamer 188)
- Sodium citrate (Rectal)
- Naldemedine
- Arachis oil
- Magnesium hydroxide
- Sodium picosulfate
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.
Management | Constipation | CKS | NICE
The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.
Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.
Treatment with prucalopride (October 2019 review)
1. Patient should have been treated with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, and these treatments have failed to provide adequate relief and invasive treatment for constipation is being considered.
2. If treatment is not effective after 4 weeks then consider stopping treatment.